103 related articles for article (PubMed ID: 26024481)
1. The Unique Non-Catalytic C-Terminus of P37delta-PI3K Adds Proliferative Properties In Vitro and In Vivo.
Ejeskär K; Vickes O; Kuchipudi A; Wettergren Y; Uv A; Rotter Sopasakis V
PLoS One; 2015; 10(5):e0127497. PubMed ID: 26024481
[TBL] [Abstract][Full Text] [Related]
2. p37δ is a new isoform of PI3K p110δ that increases cell proliferation and is overexpressed in tumors.
Fransson S; Uv A; Eriksson H; Andersson MK; Wettergren Y; Bergo M; Ejeskär K
Oncogene; 2012 Jul; 31(27):3277-86. PubMed ID: 22020336
[TBL] [Abstract][Full Text] [Related]
3. High level of p37δ-mRNA relative to p110δ-mRNA in neuroblastoma tumors correlates with poor patient survival.
Fransson S; Ejeskär K
Med Oncol; 2013 Dec; 30(4):724. PubMed ID: 24026661
[TBL] [Abstract][Full Text] [Related]
4. Direct positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase.
Chagpar RB; Links PH; Pastor MC; Furber LA; Hawrysh AD; Chamberlain MD; Anderson DH
Proc Natl Acad Sci U S A; 2010 Mar; 107(12):5471-6. PubMed ID: 20212113
[TBL] [Abstract][Full Text] [Related]
5. Activation of PI3K/Akt signaling by n-terminal SH2 domain mutants of the p85α regulatory subunit of PI3K is enhanced by deletion of its c-terminal SH2 domain.
Hofmann BT; Jücker M
Cell Signal; 2012 Oct; 24(10):1950-4. PubMed ID: 22735814
[TBL] [Abstract][Full Text] [Related]
6. Expression of a mutated form of the p85alpha regulatory subunit of phosphatidylinositol 3-kinase in a Hodgkin's lymphoma-derived cell line (CO).
Jücker M; Südel K; Horn S; Sickel M; Wegner W; Fiedler W; Feldman RA
Leukemia; 2002 May; 16(5):894-901. PubMed ID: 11986952
[TBL] [Abstract][Full Text] [Related]
7. Class IA PI3K regulatory subunits: p110-independent roles and structures.
Fox M; Mott HR; Owen D
Biochem Soc Trans; 2020 Aug; 48(4):1397-1417. PubMed ID: 32677674
[TBL] [Abstract][Full Text] [Related]
8. A Cross-Species Study of PI3K Protein-Protein Interactions Reveals the Direct Interaction of P85 and SHP2.
Breitkopf SB; Yang X; Begley MJ; Kulkarni M; Chiu YH; Turke AB; Lauriol J; Yuan M; Qi J; Engelman JA; Hong P; Kontaridis MI; Cantley LC; Perrimon N; Asara JM
Sci Rep; 2016 Feb; 6():20471. PubMed ID: 26839216
[TBL] [Abstract][Full Text] [Related]
9. Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway.
Meng Q; Xia C; Fang J; Rojanasakul Y; Jiang BH
Cell Signal; 2006 Dec; 18(12):2262-71. PubMed ID: 16839745
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of p85, the non-catalytic subunit of phosphatidylinositol 3-kinase, exerts potent antitumor activity in human breast cancer cells.
Folgiero V; Di Carlo SE; Bon G; Spugnini EP; Di Benedetto A; Germoni S; Pia Gentileschi M; Accardo A; Milella M; Morelli G; Bossi G; Mottolese M; Falcioni R
Cell Death Dis; 2012 Dec; 3(12):e440. PubMed ID: 23222510
[TBL] [Abstract][Full Text] [Related]
11. Ras-dependent and Ras-independent effects of PI3K in Drosophila motor neurons.
Johnson C; Chun-Jen Lin C; Stern M
Genes Brain Behav; 2012 Oct; 11(7):848-58. PubMed ID: 22783951
[TBL] [Abstract][Full Text] [Related]
12. Expression pattern of class I phosphoinositide 3-kinase and distribution of its product, phosphatidylinositol-3,4,5-trisphosphate, during Drosophila embryogenesis.
Xi X; Tatei K; Kihara Y; Izumi T
Gene Expr Patterns; 2014 Jul; 15(2):88-95. PubMed ID: 24928809
[TBL] [Abstract][Full Text] [Related]
13. The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factors.
Wu CJ; O'Rourke DM; Feng GS; Johnson GR; Wang Q; Greene MI
Oncogene; 2001 Sep; 20(42):6018-25. PubMed ID: 11593409
[TBL] [Abstract][Full Text] [Related]
14. Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells.
Peng Y; Li L; Huang M; Duan C; Zhang L; Chen J
Cell Signal; 2014 Dec; 26(12):2782-92. PubMed ID: 25193113
[TBL] [Abstract][Full Text] [Related]
15. Interaction of the retinal insulin receptor beta-subunit with the p85 subunit of phosphoinositide 3-kinase.
Rajala RV; McClellan ME; Chan MD; Tsiokas L; Anderson RE
Biochemistry; 2004 May; 43(19):5637-50. PubMed ID: 15134438
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of constitutive phosphoinositide 3-kinase activation by oncogenic mutants of the p85 regulatory subunit.
Shekar SC; Wu H; Fu Z; Yip SC; Nagajyothi ; Cahill SM; Girvin ME; Backer JM
J Biol Chem; 2005 Jul; 280(30):27850-5. PubMed ID: 15932879
[TBL] [Abstract][Full Text] [Related]
17. The inhibition of p85αPI3KSer83 phosphorylation prevents cell proliferation and invasion in prostate cancer cells.
Feola A; Cimini A; Migliucci F; Iorio R; Zuchegna C; Rothenberger R; Cito L; Porcellini A; Unteregger G; Tombolini V; Giordano A; Di Domenico M
J Cell Biochem; 2013 Sep; 114(9):2114-9. PubMed ID: 23553770
[TBL] [Abstract][Full Text] [Related]
18. BRD7, a tumor suppressor, interacts with p85α and regulates PI3K activity.
Chiu YH; Lee JY; Cantley LC
Mol Cell; 2014 Apr; 54(1):193-202. PubMed ID: 24657164
[TBL] [Abstract][Full Text] [Related]
19. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
20. PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells.
Kaarbø M; Mikkelsen OL; Malerød L; Qu S; Lobert VH; Akgul G; Halvorsen T; Maelandsmo GM; Saatcioglu F
Cell Oncol; 2010; 32(1-2):11-27. PubMed ID: 20203370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
